Postoperative opioid-free ureteroscopy discharge : A quality initiative pilot protocol
Copyright © 2021 The Authors. Published by Wolters Kluwer Health, Inc..
BACKGROUND: Opioids are commonly prescribed after ureteroscopy. With an increasing adoption of ureteroscopy for management of urolithiasis, this subset of patients is at high risk for opioid dependence. We sought to pilot an opioid-free discharge protocol for patients undergoing ureteroscopy for urolithiasis.
MATERIALS AND METHODS: A prospective cohort study was performed of all patients undergoing ureteroscopy for urolithiasis and compared them to a historical control group. An opioid-free discharge protocol was initiated targeting all areas of surgical care from June 20th, 2019 to September 20th, 2019 as part of an institutional quality improvement initiative. Demographic and surgical data were collected as were morphine equivalent doses (MEDs) prescribed at discharge, postoperative measures including phone calls, clinic visits, and emergency room visits for pain.
RESULTS: Between October 1st, 2017 and February 1st, 2018, a total of 54 patients who underwent ureteroscopy were identified and comprised the historical control cohort while 54 prospective patients met the inclusion criteria since institution of the quality improvement initiative. There were no statistically significant differences in baseline patient demographics or surgical characteristics between the 2 patient groups. Total 37% of the intervention group had a preexisting opioid prescription versus 42.6% of the control group with no difference in preoperative MED (p = 0.55). The intervention group had a mean MED of 12.03 at discharge versus 110.5 in the control cohort (p ≤ 0.001). At discharge 3.7% of the intervention group received an opioid prescription versus 88.9% of the control group (p < 0.001). Overall, there was no difference in postoperative pain related phone calls (p = 1.0) or emergency room visits (p = 1.0).
CONCLUSIONS: An opioid-free discharge protocol can dramatically reduce opioid prescription at discharge following ureteroscopy for urinary calculi without affecting postoperative measures such as phone calls, clinic visits, or subsequent prescriptions.
| Errataetall: |
CommentIn: J Urol. 2022 Jun;207(6):1342-1344. - PMID 35300510 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Current urology - 15(2021), 3 vom: 22. Sept., Seite 176-180 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kasman, Alex M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 03.04.2024 published: Print-Electronic CommentIn: J Urol. 2022 Jun;207(6):1342-1344. - PMID 35300510 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1097/CU9.0000000000000025 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330942131 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330942131 | ||
| 003 | DE-627 | ||
| 005 | 20240403233649.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/CU9.0000000000000025 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1362.xml |
| 035 | |a (DE-627)NLM330942131 | ||
| 035 | |a (NLM)34552459 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kasman, Alex M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Postoperative opioid-free ureteroscopy discharge |b A quality initiative pilot protocol |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: J Urol. 2022 Jun;207(6):1342-1344. - PMID 35300510 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2021 The Authors. Published by Wolters Kluwer Health, Inc. | ||
| 520 | |a BACKGROUND: Opioids are commonly prescribed after ureteroscopy. With an increasing adoption of ureteroscopy for management of urolithiasis, this subset of patients is at high risk for opioid dependence. We sought to pilot an opioid-free discharge protocol for patients undergoing ureteroscopy for urolithiasis | ||
| 520 | |a MATERIALS AND METHODS: A prospective cohort study was performed of all patients undergoing ureteroscopy for urolithiasis and compared them to a historical control group. An opioid-free discharge protocol was initiated targeting all areas of surgical care from June 20th, 2019 to September 20th, 2019 as part of an institutional quality improvement initiative. Demographic and surgical data were collected as were morphine equivalent doses (MEDs) prescribed at discharge, postoperative measures including phone calls, clinic visits, and emergency room visits for pain | ||
| 520 | |a RESULTS: Between October 1st, 2017 and February 1st, 2018, a total of 54 patients who underwent ureteroscopy were identified and comprised the historical control cohort while 54 prospective patients met the inclusion criteria since institution of the quality improvement initiative. There were no statistically significant differences in baseline patient demographics or surgical characteristics between the 2 patient groups. Total 37% of the intervention group had a preexisting opioid prescription versus 42.6% of the control group with no difference in preoperative MED (p = 0.55). The intervention group had a mean MED of 12.03 at discharge versus 110.5 in the control cohort (p ≤ 0.001). At discharge 3.7% of the intervention group received an opioid prescription versus 88.9% of the control group (p < 0.001). Overall, there was no difference in postoperative pain related phone calls (p = 1.0) or emergency room visits (p = 1.0) | ||
| 520 | |a CONCLUSIONS: An opioid-free discharge protocol can dramatically reduce opioid prescription at discharge following ureteroscopy for urinary calculi without affecting postoperative measures such as phone calls, clinic visits, or subsequent prescriptions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Opioid free | |
| 650 | 4 | |a Opioid sparing | |
| 650 | 4 | |a Ureteroscopy | |
| 700 | 1 | |a Schmidt, Bogdana |e verfasserin |4 aut | |
| 700 | 1 | |a Spradling, Kyle |e verfasserin |4 aut | |
| 700 | 1 | |a Chow, Charlene |e verfasserin |4 aut | |
| 700 | 1 | |a Hunt, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Mechele |e verfasserin |4 aut | |
| 700 | 1 | |a Sockol, Alexa |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Joseph |e verfasserin |4 aut | |
| 700 | 1 | |a Leppert, John T |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Jay |e verfasserin |4 aut | |
| 700 | 1 | |a Conti, Simon L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current urology |d 2012 |g 15(2021), 3 vom: 22. Sept., Seite 176-180 |w (DE-627)NLM239073851 |x 1661-7649 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2021 |g number:3 |g day:22 |g month:09 |g pages:176-180 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/CU9.0000000000000025 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2021 |e 3 |b 22 |c 09 |h 176-180 | ||